157 related articles for article (PubMed ID: 34855250)
1. Keratoacanthoma or cutaneous squamous cell carcinoma revealing a DNA mismatch repair default (Muir-Torre Syndrome).
Miao Y; Kolb F; Tomasic G; Lupu J; Routier E; Robert C
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():74-76. PubMed ID: 34855250
[TBL] [Abstract][Full Text] [Related]
2. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
3. Family with MSH2 mutation presenting with keratoacanthoma and precancerous skin lesions.
Hatta N; Takata A; Ishizawa S; Niida Y
J Dermatol; 2015 Nov; 42(11):1087-90. PubMed ID: 26077460
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
5. A locally advanced colon cancer patient with Muir-Torre syndrome obtains durable response to neoadjuvant and adjuvant immunotherapy.
Guo Z; Cai Y; Yin W; Huang J
Tumori; 2023 Dec; 109(6):NP27-NP31. PubMed ID: 37880978
[TBL] [Abstract][Full Text] [Related]
6. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
7. Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.
Everett JN; Raymond VM; Dandapani M; Marvin M; Kohlmann W; Chittenden A; Koeppe E; Gustafson SL; Else T; Fullen DR; Johnson TM; Syngal S; Gruber SB; Stoffel EM
JAMA Dermatol; 2014 Dec; 150(12):1315-21. PubMed ID: 25006859
[TBL] [Abstract][Full Text] [Related]
8. [Muir-Torre syndrome with previously undescribed frameshift mutation in the MSH2 gene].
Gilly B; Unholzer A; Strobl-Wildemann G; Haas C; Starz H; Welzel J
Hautarzt; 2013 Apr; 64(4):290-4. PubMed ID: 23229822
[TBL] [Abstract][Full Text] [Related]
9. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
10. A case of Muir-Torre syndrome with a keratoacanthoma and sebaceous neoplasms: Clinicopathological features and a speculation on the pathogenesis of cutaneous tumor type.
Takayama E; Yoshioka A; Takai T; Goto K
J Dermatol; 2021 May; 48(5):690-694. PubMed ID: 33523490
[TBL] [Abstract][Full Text] [Related]
11. [Muir-Torre syndrome: rare association with duodenal carcinoma].
Bacha D; Deschamps L; Sauvanet A; Couvelard A
Ann Pathol; 2009 Dec; 29(6):495-8. PubMed ID: 20005439
[TBL] [Abstract][Full Text] [Related]
12. Biallelic MYH germline mutations as cause of Muir-Torre syndrome.
Guillén-Ponce C; Castillejo A; Barberá VM; Pascual-Ramírez JC; Andrada E; Castillejo MI; Guarinós C; Molina-Garrido MJ; Carrato A; Soto JL
Fam Cancer; 2010 Jun; 9(2):151-4. PubMed ID: 19998059
[TBL] [Abstract][Full Text] [Related]
13. [Female patient with Muir-Torre syndrome].
Negraszus N; Jöhrens K; Bertelmann E
Ophthalmologe; 2010 Nov; 107(11):1059-62. PubMed ID: 20393721
[TBL] [Abstract][Full Text] [Related]
14. A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome.
Perera S; Ramyar L; Mitri A; Pollett A; Gallinger S; Speevak MD; Aronson M; Bapat B
J Hum Genet; 2010 Jan; 55(1):37-41. PubMed ID: 19911012
[TBL] [Abstract][Full Text] [Related]
15. Muir-Torre Syndrome: expanding the genotype and phenotype--a further family with a MSH6 mutation.
Murphy HR; Armstrong R; Cairns D; Greenhalgh KL
Fam Cancer; 2008; 7(3):255-7. PubMed ID: 18236172
[TBL] [Abstract][Full Text] [Related]
16. Muir-Torre Syndrome with Novel Mutation in the MSH2 Gene.
Ustaoglu E; Agirgol S; Aymelek HS; Turhan EI
Acta Dermatovenerol Croat; 2023 Dec; 31(3):144-147. PubMed ID: 38439724
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome.
Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML
Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734
[TBL] [Abstract][Full Text] [Related]
18. Solitary subungual keratoacanthoma arising in an MSH2 germline mutation carrier: confirmation of a relationship by immunohistochemical analysis.
Stoebner PE; Fabre C; Delfour C; Joujoux JM; Roger P; Dandurand M; Meunier L
Dermatology; 2009; 219(2):174-8. PubMed ID: 19602866
[TBL] [Abstract][Full Text] [Related]
19. The frequency of Muir-Torre syndrome among Lynch syndrome families.
South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
[TBL] [Abstract][Full Text] [Related]
20. Muir-Torre syndrome: sebaceous carcinoma concurrent with colon cancer in a kidney transplant recipient; a case report.
Tomonari M; Shimada M; Nakada Y; Yamamoto I; Itoh M; Koike Y; Kobayashi A; Miki J; Yamada H; Kimura T; Saito S; Sugano K; Sekine S; Yamamoto H; Asahina A; Yokoo T
BMC Nephrol; 2019 Oct; 20(1):394. PubMed ID: 31664942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
